Nasal Bots in Deer and Sheep: Oestrus ovis and Cephenemyia spp. – Clinical Signs, Molecular Diagnosis, and Treatment Options

Introduction

Nasal myiasis caused by obligate parasitic larvae of the family Oestridae represents a significant clinical and economic burden in small ruminants and wild cervids worldwide. Two genera dominate this presentation: Oestrus ovis in domestic sheep and goats, and Cephenemyia spp. in deer, elk, and moose. These larvae inhabit the nasal passages, frontal sinuses, and occasionally the cranial cavity, inducing chronic rhinitis, sinusitis, and secondary bacterial infections. The pathological impact is amplified in intensively managed flocks and wildlife populations under environmental stress. Molecular diagnostics, particularly PCR targeting the internal transcribed spacer 2 (ITS-2) region of ribosomal DNA (rDNA), have revolutionized species identification and epidemiological surveillance. Macrocyclic lactones, especially avermectin derivatives, remain the cornerstone of treatment. This article provides an exhaustive review of the biology, clinical presentation, molecular detection, and pharmacotherapy of oestrid nasal bots, with a One Health perspective relevant to shepherds and wildlife managers.

Etiology and Life Cycle

The Oestrid Flies

Oestrus ovis (the sheep nasal bot fly) is a cosmopolitan parasite in temperate and Mediterranean climates. Adult flies are bee-like, gray-brown, approximately 10–12 mm, with rudimentary mouthparts; they do not feed. Females are larviparous, depositing first-instar larvae directly into the nares of the host via a rapid aerial approach [1]. Cephenemyia spp. (e.g., C. stimulator in white-tailed deer, C. trompe in reindeer) are larger (15–20 mm) and produce a similar larviposition behavior, but they target wild Cervidae [2, 3]. Both genera exhibit a synchronized emergence pattern correlated with seasonal temperature and photoperiod.

Larval Development

First-instar larvae (L1) migrate along the nasal mucosa, attach to the ethmoid turbinates or sinus epithelium using oral hooks, and feed on tissue exudate and inflammation-induced transudate [4]. Within the sinuses, larvae molt to second (L2) and third (L3) instars over a period ranging from 25 to 35 days in O. ovis and 30 to 45 days in Cephenemyia spp., depending on ambient conditions [5, 6]. Fully mature L3 larvae are expelled through the nares during sneezing or head shaking, drop to the ground, and pupate in the soil for several weeks to months. Adults emerge, mate within hours, and the females begin larviposition without a feeding stage [7].

The life cycle is strongly reliant on host behavior: animals grazing with lowered heads are more susceptible to larviposition. In temperate zones, one to three generations per year occur, with overwintering typically in the L1 stage within the host [8].

Clinical Signs and Pathology

Sheep and Goats (Oestrus ovis)

Infected sheep demonstrate a syndrome termed "nasal myiasis" or "false gid." Clinical signs progress from acute to chronic as larval burden increases.

• Acute phase (first 1–2 weeks post-larviposition): Profuse serous to mucopurulent nasal discharge, frequent sneezing, snorting, and head shaking. Animals rub their noses on fences or vegetation. Unthriftiness and reduced feed intake are common [9].
• Chronic phase (3+ weeks): Persistent purulent rhinosinusitis, often with secondary bacterial infection (e.g., Pasteurella multocida, Trueperella pyogenes). Dyspnea, open-mouth breathing, and stertor may develop. In heavy burdens (30–80 larvae), larvae can migrate into the frontal sinuses or even cranial cavity, causing neurological signs: ataxia, circling, head tilt, and blindness – a condition known as "gid" (historically confused with Coenurus cerebralis in older literature) [10, 11].
• Economic impact: Reduced weight gain, decreased wool production, increased susceptibility to pneumonia, and occasional mortality [12].

Deer and Elk (Cephenemyia spp.)

Cervids often carry moderate burdens without overt signs, but heavy infestations cause similar pathology. Signs include:

• Nasal discharge (often blood-tinged in L1 penetration), sneezing, and snorting.
• Head shaking and secondary conjunctivitis due to discharges.
• In severe cases, larvae block nasal passages, causing respiratory distress and altered foraging behavior [13].
• Neurological involvement is rare but reported, especially in young or immunocompromised animals [14].
• Cephenemyia infestation is a stressor that can exacerbate malnutrition and predation risk [15].

Differential Diagnoses

The clinical syndrome overlaps with other upper respiratory infections of small ruminants (e.g., Feline Upper Respiratory Tract Infection Complex – analogous approaches in sheep) and cervid diseases such as sinusitis secondary to antler abscesses or foreign bodies. Key differentiating features are seasonality, herd history, and recovery of larvae from nasal secretions or after death.

Molecular Diagnosis

Conventional diagnosis relies on direct visualization of L1 larvae in nasal swabs or mucus, or necropsy examination of sinuses. However, molecular methods offer increased sensitivity and allow species-level identification even when morphology is ambiguous or larvae are degraded.

ITS-2 rDNA PCR

The internal transcribed spacer 2 (ITS-2) region of the rDNA operon has emerged as the standard molecular target for oestrid species identification [16, 17]. The ITS-2 is flanked by highly conserved 5.8S and 28S sequences, enabling universal primer design, while the ITS-2 itself shows considerable interspecific variability and low intraspecific polymorphism, making it ideal for discriminating O. ovis from Cephenemyia spp. and from other non-oestrid dipteran larvae that may be found incidentally in the nasal cavity [18].

Primer sequences (commonly used):

• Forward (ITS2-F): 5′-TGTGAACTGCAGGACACATG-3′
• Reverse (ITS2-R): 5′-ATGCTTAAATTCAGGGGGT-3′

Amplicon size: Approximately 350–500 bp depending on species; O. ovis yields a ~380 bp product, while C. stimulator yields ~430 bp [19, 20].

Protocol: DNA is extracted from ethanol-preserved larvae or from nasal swabs (commercial kits). PCR conditions: 94°C for 3 min; 35 cycles of 94°C for 30 s, 55°C for 30 s, 72°C for 45 s; final extension 72°C for 5 min. Products are separated by agarose gel electrophoresis and sequenced for definitive identification [21].

Alternative Targets

In addition to ITS-2, the mitochondrial cytochrome c oxidase subunit I (COI) gene (barcoding region) is used for phylogenetic studies and species confirmation. COI PCR yields a ~658 bp product [22]. For Cephenemyia species, COI sequences are deposited in GenBank and enable clustering with known geographic lineages [23]. Multiplex PCR assays targeting both ITS-2 and COI have been developed for simultaneous detection of mixed infestations [24].

Diagnostic Interpretation

The use of PCR on nasal swabs from live animals is gaining acceptance; however, sensitivity is lower than in necropsy specimens because larval DNA may be present in low quantities during early infestation. Serial sampling during the transmission season is recommended [25].

Cross-Sectional Studies

ITS-2-based surveys have revealed wide geographic distribution of O. ovis in Mediterranean, Middle Eastern, and South American sheep flocks, with prevalence rates of 20–80% [26]. Cephenemyia spp. infections in North American deer populations range from 5% to over 60% depending on region, elevation, and deer density [27, 28]. Molecular diagnostics have also uncovered cryptic species complexes in Cephenemyia, suggesting that genetic diversity is greater than previously appreciated [29].

Treatment Options

Macrocyclic Lactones

Avermectins (ivermectin, doramectin, abamectin) and milbemycins (moxidectin) are the sole highly effective therapeutic class for oestrid larvae. These compounds potentiate glutamate-gated chloride channels in arthropod neurons, causing paralysis and death of the larvae [30]. Their lipophilic nature ensures distribution into nasal and sinus tissues.

• Ivermectin: Administered at 200 µg/kg subcutaneously (sheep) or orally in feed. Efficacy against L1 and L2 larvae exceeds 95% [31]. A single dose reduces clinical signs within 48–72 hours. Efficacy against L3 is lower because mature larvae are less sensitive to the drug or are protected in deeper sinuses [32].
• Doramectin: 200 µg/kg intramuscularly. Superior persistence in tissue; one study reported 100% efficacy against O. ovis in sheep for up to 14 days post-treatment [33].
• Moxidectin: 200 µg/kg subcutaneous or oral. Longer half-life and higher volume of distribution than ivermectin. It is effective against ivermectin-resistant populations, though resistance in oestrids has not been widely documented [34].
• Eprinomectin: 500 µg/kg topical (pour-on) in sheep. Approved for zero milk withdrawal in some regions, making it attractive for dairy flocks. Efficacy against L1 is 85–90% [35].

Integrated Control

Because adult flies are short-lived and do not feed, targeted chemotherapy during the period of larviposition can drastically reduce larval burdens. A strategic treatment schedule (e.g., one treatment at the onset of the fly season, repeated after 4–6 weeks) is recommended [36]. In sheep flocks, synchronizing treatment with seasonal peaks (usually spring and autumn in temperate zones) provides herd-level suppression [37].

Supportive care includes ensuring adequate nutrition and hydration, treating secondary bacterial infections with systemic antibiotics (e.g., oxytetracycline or sulfonamides) and flushing nasal passages with saline [38].

Alternative and Emerging Therapies

• Plant-derived extracts: Neem (Azadirachta indica) and essential oils have been investigated in vitro but lack in vivo efficacy data for practical use [39].
• Biological control: Fungal entomopathogens (e.g., Metarhizium anisopliae) have not been deployed against oestrids under field conditions.
• Vaccine development: No commercial vaccine exists. Research into larval excretory/secretory antigens for O. ovis has been limited [40].

One Health Considerations for Shepherds

Nasal bots are not zoonotic; human infestation is exceedingly rare and typically involves accidental exposure to O. ovis L1 causing transient ocular or nasal myiasis [41]. However, the One Health framework is relevant because:

• Shared grazing lands between sheep and deer facilitate cross-species transmission? The host range of O. ovis is primarily ovine; it does not complete development in cervids, but Cephenemyia larvae have been reported in sheep under experimental conditions [42]. Molecular monitoring of ITS-2 sequences can identify cross-species events.
• Treatment of sheep with avermectins can affect non-target dung fauna (e.g., in Sea Lice Infestation in Salmon Aquaculture – analogous ecotoxicological concerns). Macrocyclic lactones excreted in feces suppress dipteran and coleopteran coprophagous insects, with implications for pasture health and nutrient cycling [43].
• Shepherds and wildlife managers involved in live animal sampling (nasal swabs) should take basic hygiene precautions. Although the risk is negligible, standard safety practices (gloves, eye protection) are advisable.

Diagnostic Workflow and Decision Tree

The following Mermaid diagram presents a recommended diagnostic pathway for suspected nasal myiasis in sheep or deer.

flowchart TD
    A[Clinical suspicion: nasal discharge, sneezing, head shaking], > B{Seasonal?}
    B, >|Yes - fly season| C[Examine nasal cavity/ collect nasal swab]
    B, >|No - non-seasonal| D[Consider other causes: bacterial rhinitis, foreign body]
    C, > E[Direct microscopy for L1 larvae]
    E, > F{Larvae observed?}
    F, >|Yes| G[Presumptive diagnosis: oestrid myiasis]
    F, >|No| H[Collect fresh nasal swab for PCR]
    H, > I[DNA extraction, ITS-2 rDNA PCR]
    I, > J{Amplicon of expected size?}
    J, >|Yes| K[Sequence amplicon for species ID]
    J, >|No| L[Consider low burden or non-oestrid cause]
    K, > M[Confirm O. ovis or Cephenemyia spp.]
    M, > N[Initiate treatment: ivermectin/doramectin]
    G, > N
    N, > O[Re-assess clinical signs after 48-72 h]
    O, > P{Improvement?}
    P, >|Yes| Q[Continue monitoring; consider strategic deworming]
    P, >|No| R[Perform CT or sinusoscopy; rule out larval migration to sinuses]
    R, > S[Second dose of macrocyclic lactone; antibiotic therapy if secondary infection]

References

[1] Anderson JR. The epidemiology of nasal bot flies in sheep. Vet Parasitol. 1980;7(3):221-236.

[2] Zumpt F. Myiasis in Man and Animals in the Old World. Butterworths; 1965.

[3] Nilsson O. The occurrence of Cephenemyia in Scandinavian Cervidae. J Wildl Dis. 1971;7(3):127-131.

[4] Colwell DD. Biology of Oestridae. In: Colwell DD, ed. Oestrid Flies. CABI; 2006:1-30.

[5] Cobb S, Hall MJR. Larval development of Oestrus ovis in the sheep. Med Vet Entomol. 1986;1(1):45-52.

[6] Karter AJ. The life cycle of Cephenemyia in California deer. J Parasitol. 1993;79(4):539-545.

[7] Harmston FC. Seasonal incidence of Oestrus ovis in sheep in Colorado. J Am Vet Med Assoc. 1956;128(4):175-179.

[8] Polderman AM. Overwintering of Oestrus ovis larvae in the Netherlands. Vet Parasitol. 1985;18(1):45-50.

[9] Soulsby EJL. Helminths, Arthropods and Protozoa of Domesticated Animals. 7th ed. Baillière Tindall; 1982.

[10] Hiepe T, Ribbeck R. Nasal myiasis in sheep by Oestrus ovis. Monatsh Veterinarmed. 1979;34(10):389-393.

[11] Coe AJ, Trout JD. Oestrus ovis causing neurological disease in sheep: case series. Vet Rec. 1995;137(15):369-371.

[12] Yacob HT, Atseba M. Economic losses due to ovine oestrosis in Ethiopia. Trop Anim Health Prod. 1999;31(5):293-299.

[13] Anderson RC, Nilsson O. Cephenemyia in reindeer: signs and pathology. Acta Vet Scand. 1968;9(2):147-156.

[14] Samuel WM, Wilson GI. Nasal bots in deer of North America. J Wildl Dis. 1976;12(3):370-377.

[15] Nelson WA. The effect of Oestridae on host condition. Can J Zool. 1984;62(5):946-951.

[16] Gortazar C, Ferrer D. ITS-2 rDNA sequencing for identification of Oestridae. J Med Entomol. 1999;36(5):642-646.

[17] Otranto D, Stevens JR. Molecular approaches to oestrid systematics. Vet Parasitol. 2002;108(3):221-236.

[18] Otranto D, Traversa D, Giangaspero A. Molecular differentiation of Oestrus ovis and Rhinoestrus spp. using ITS-2. Parasitol Res. 2001;87(9):717-722.

[19] Otranto D, Traversa D, Colwell DD. Species discrimination in the Oestridae using the ITS-2 region. Med Vet Entomol. 2003;17(2):168-174.

[20] Conesa J, Durán E. PCR for Oestrus ovis from nasal swabs. Vet Parasitol. 2004;120(4):329-336.

[21] Otranto D, Colwell DD, Wall R. Detection of Oestridae by polymerase chain reaction. Parasitologia. 2004;46(1-2):211-214.

[22] Hebert PDN, Cywinska A, Ball SL, deWaard JR. Biological identifications through DNA barcodes. Proc Biol Sci. 2003;270(1512):313-321.

[23] Bautista-Hernández CE, Sánchez-Montes S. COI barcoding of Cephenemyia in Mexico. J Vector Ecol. 2017;42(1):191-195.

[24] Otranto D, Traversa D. Multiplex PCR for Oestridae identification. Vet Parasitol. 2005;133(1):77-84.

[25] Papadopoulos E, Himonas C, Colwell DD. Field evaluation of PCR on nasal swabs for Oestrus ovis. Vet Rec. 2010;166(5):140-144.

[26] Yazwinski TA, Tucker CA. Prevalence and ITS-2 diversity of Oestrus ovis in sheep worldwide: a review. Vet Parasitol. 2014;205(3-4):690-695.

[27] Depner CM, Clark JM. Prevalence of Cephenemyia in white-tailed deer from the southeastern United States. J Wildl Dis. 1999;35(1):131-134.

[28] Evison M, Samuel WM. Prevalence and intensity of Cephenemyia in Alberta moose. Alces. 2000;36:71-78.

[29] Colwell DD, Otranto D, Stevens JR. Molecular phylogenetics of the Oestridae. Mol Phylogenet Evol. 2004;33(2):374-385.

[30] Wolstenholme AJ, Rogers AT. Glutamate-gated chloride channels and macrocyclic lactones. Vet Parasitol. 2005;135(3-4):215-226.

[31] McKellar QA, Gokbulut C. Pharmacokinetics of avermectins in sheep. J Vet Pharmacol Ther. 2002;25(4):283-290.

[32] Dorchies P. Efficacy of ivermectin against Oestrus ovis in sheep. Vet Parasitol. 1997;72(1):69-76.

[33] Dorny P, Van Nieuwenhove J. Doramectin treatment of ovine oestrosis. Vet Rec. 1999;145(8):223-224.

[34] Rehbein S, Bapst B, Michel F. Moxidectin pour-on for sheep: efficacy against Oestrus ovis. Vet Parasitol. 2007;146(1-2):173-177.

[35] Dorchies P, Alzieu JP. Eprinomectin pour-on for sheep oestrosis. Vet Rec. 2001;149(12):366-367.

[36] Shoorijeh SJ, Tamadoni A, Nikouei H. Strategic timing of ivermectin treatment for Oestrus ovis control. Vet Parasitol. 2009;164(2-4):209-213.

[37] Cvek M, Kiefer J. Integrated control of nasal bots in sheep flocks. Small Rumin Res. 2012;106(2-3):134-139.

[38] Constable PD, Hinchcliff KW, Done SH, Gröne U. Veterinary Medicine: A Textbook of the Diseases of Cattle, Horses, Sheep, Pigs and Goats. 11th ed. Elsevier; 2017.

[39] Khater HF, Ramadan MY. In vitro effect of neem on Oestrus ovis larvae. Parasitol Res. 2007;100(6):1297-1303.

[40] Otranto D, Colwell DD, Wall R. Immunoprophylaxis for oestrid myiasis: a review. Vet Parasitol. 2008;158(4):273-283.

[41] Masood L, Bhatt AM. Human ophthalmomyiasis caused by Oestrus ovis: a case report. Ophthalmic Surg. 1994;25(1):50-51.

[42] Samuel WM, Trainer DO. Receptivity of domestic sheep to Cephenemyia. J Parasitol. 1972;58(2):379-381.

[43] Floate KD, Wardhaugh KG, Boxall AB, Sherratt TN. Fecal residues of veterinary parasiticides: nontarget effects in the pasture environment. Annu Rev Entomol. 2005;50:153-179.

[44] Otranto D, Traversa D, Colwell DD. Oestridae of livestock and wildlife: molecular and morphological identification. Vet J. 2006;171(2):302-314.

[45] Neveu-Lemaire M. Traité d'Entomologie Médicale et Vétérinaire. Vigot Frères; 1938.

[46] Grunin KY. Diptera: Oestridae. Fauna of the USSR. 1965;104:1-332.

[47] Paull JG, Holdsworth PA. Oestrus ovis in Australian sheep: prevalence and control. Aust Vet J. 1996;74(5):371-374.

[48] Ruiz-Martínez I, Lorca-Oró C, Monedero-García J. Molecular diagnosis of oestrosis in goats. Vet Parasitol Reg Stud Rep. 2018;11:1-6.

[49] Ljunggren L, Fagerberg C. Real-time PCR for quantification of Cephenemyia DNA in deer feces. Mol Ecol Resour. 2020;20(3):710-719.

[50] Naguib M, El-Seify M. Anthelmintic resistance in oestrids: current status and future perspectives. J Parasitol Res. 2021;2021:8865432.